% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Teipel:259131,
      author       = {Teipel, Stefan and Tang, Yi and Boccardi, Marina},
      title        = {{P}redicting cognitive decline in older people by
                      structural and molecular imaging.},
      journal      = {Current opinion in neurology},
      volume       = {36},
      number       = {4},
      issn         = {1350-7540},
      publisher    = {Ovid},
      reportid     = {DZNE-2023-00727},
      pages        = {253 - 263},
      year         = {2023},
      abstract     = {Availability of possible disease modifying treatments and
                      the recognition of predementia stages of Alzheimer's disease
                      (AD) have raised awareness for the prognostic and predictive
                      role of biomarkers, particularly imaging markers.The
                      positive predictive value of amyloid PET for the transition
                      to prodromal AD or AD dementia in cognitively normal people
                      is below $25\%.$ Evidence for tau PET, FDG-PET and
                      structural MRI is even more limited. In people with mild
                      cognitive impairment (MCI), imaging markers yield positive
                      predictive values above $60\%$ with moderate advantages for
                      amyloid PET over the other modalities and an added value for
                      the combination of molecular with downstream
                      neurodegeneration markers.In cognitively normal people,
                      imaging is not recommended for individual prognosis due to
                      lack of sufficient predictive accuracy. Such measures should
                      be restricted to risk enrichment in clinical trials. In
                      people with MCI, amyloid PET and, to a somewhat lesser
                      extent, tau PET, FDG-PET, and MRI yield relevant predictive
                      accuracy for clinical counseling as part of a comprehensive
                      diagnostic program in tertiary care units. Future studies
                      should focus on the systematic and patient-centered
                      implementation of imaging markers in evidence-based
                      care-pathways for people with prodromal AD.},
      subtyp        = {Review Article},
      keywords     = {Humans / Aged / Fluorodeoxyglucose F18 / Alzheimer Disease:
                      diagnostic imaging / Cognitive Dysfunction: diagnostic
                      imaging / Prognosis / Positron-Emission Tomography: methods
                      / Biomarkers / Molecular Imaging / Amyloid beta-Peptides /
                      tau Proteins / Fluorodeoxyglucose F18 (NLM Chemicals) /
                      Biomarkers (NLM Chemicals) / Amyloid beta-Peptides (NLM
                      Chemicals) / tau Proteins (NLM Chemicals)},
      cin          = {AG Boccardi / AG Teipel},
      ddc          = {610},
      cid          = {I:(DE-2719)5000062 / I:(DE-2719)1510100},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37382114},
      doi          = {10.1097/WCO.0000000000001172},
      url          = {https://pub.dzne.de/record/259131},
}